Form 8-K ELI LILLY & Co For: Jan 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
January 15, 2025 5:24 AM ESTBMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $1,010.00 price target on Eli Lilly (NYSE: LLY).
The analyst comments "Strong underlying demand persists in the incretin market with pushes and pulls across the company's preliminary 4Q release and 2025 guide. The... More
Wells Fargo Reiterates Overweight Rating on Eli Lilly (LLY)
January 15, 2025 4:59 AM ESTWells Fargo analyst Mohit Bansal reiterated an Overweight rating and $1,000.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "What is new? - This AM Lilly preannounced 4Q numbers and the numbers are weak at $13.5B revs compared to consensus at ~$14B. This appears to be driven by weak Mounjaro and Zepbound portfolio, which stood at $5.4B total compared to $6.5B consensus. Our script tracker was suggesting ~$800M miss for Mounjaro and Zep combined, and it seems as if ex-US/stocking did not come to rescue. Given LLY is talking... More
BofA Securities on Eli Lilly (LLY): 'a particularly good buying opportunity'
January 15, 2025 4:58 AM ESTBofA Securities analyst Tim Anderson reiterated a Buy rating and $997.00 price target on Eli Lilly (NYSE: LLY)
The analyst comments "We think it offers a particularly good buying opportunity. This is predicated on LLY remaining one of two incumbent companies that should... More
